spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  microRNA therapeutics 

 HSMN NewsFeed - 13 Jun 2017
Regulus Promotes Mark Deeg, M.D. PhD to Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Jun 2017
Regulus Announces Pipeline Updates and Advancements
Biopharmaceuticals
 HSMN NewsFeed - 20 Jun 2016
Regulus Secures $30 Million Growth Capital Credit Facility
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 25 Aug 2015
Regulus Appoints Michael Huang, M.D. as Vice President, Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jun 2015
Alnylam Appoints David-Alexandre Gros, M.D., Senior Vice President, Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Jul 2014
Alnylam Elects Amy Schulman to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Jun 2014
Regulus Appoints Paul C. Grint, M.D. as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Feb 2014
Regulus Appoints Head of Regulus microMarkers(TM) R&D Division
Biopharmaceuticlas Personnel
 HSMN NewsFeed - 4 Feb 2014
Regulus Strengthens Executive Management Team with Addition of David Szekeres as Chief Business Officer and General Counsel
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Jan 2014
Alnylam and Genzyme Form Transformational Alliance for RNAi Therapeutics as Genetic Medicines
Biopharmaceuticals Licensing
 HSMN NewsFeed - 27 Nov 2012
Regulus Appoints Victor Knopov, Ph.D. as Vice President, Pharmaceutical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Jun 2012
Alnylam Expands and Develops Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Jul 2011
Genzyme and Isis Announce Submission of European Marketing Authorization Application for Mipomersen (Kynamro(R))
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 29 Jun 2011
Alnylam Files Answer and Counterclaim Related to Tekmira Lawsuit
Biopharmaceuticals Litigation
 HSMN NewsFeed - 13 Jun 2011
Alnylam Appoints Akshay Vaishnaw as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 May 2011
Regulus Therapeutics Expands Executive Team with Recent Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Mar 2011
Regulus Therapeutics Appoints Lars Karlsson, M.D., Ph.D., VP of Immunology and Fibrosis
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jan 2011
Regulus Therapeutics Promotes Garry E. Menzel, Ph.D., to Chief Operating Officer and Executive Vice President of Finance
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Dec 2010
Alnylam Elects Marsha Fanucci to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Dec 2010
Regulus Therapeutics Strengthens Immunology Leadership Team with New Key Appointment
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Oct 2010
Sanofi-Aventis Completes $10 Million Equity Investment in Regulus Therapeutics
Biopharmaceuticals
 HSMN NewsFeed - 11 Jan 2010
Regulus Therapeutics Appoints Zachary A. Zimmerman, Ph.D., Director of Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Jan 2010
Alnylam Provides Key Goals and Guidance for Next 12 to 18 Months
Biopharmaceuticals
 HSMN NewsFeed - 20 May 2009
Genzyme and Isis Announce that Mipomersen Phase 3 Study in Patients with Homozygous Familial Hypercholesterolemia Met Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 21 Jan 2009
Alnylam and Collaborators at Harvard Medical School Demonstrate In Vivo Silencing of Key Genes Implicated in the Transmission of Herpes Simplex Virus-2 (HSV-2)
Biopharmaceuticals
 HSMN NewsFeed - 20 Jan 2009
Alnylam Provides Update on Kreutzer-Limmer Patent Family
Biopharmaceuticals
 HSMN NewsFeed - 3 Dec 2008
Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Oct 2008
Alnylam Appoints Industry Leader John Schmidt as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Sep 2008
Regulus Therapeutics Appoints Dr. Stelios Papadopoulos to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Aug 2008
Regulus Therapeutics Appoints Garry Menzel, Ph.D., as Executive Vice President Corporate Development and Finance
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Jul 2008
Isis Announces Appointment of Martin P. Bedigian, M.D. as Vice President and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jul 2008
Abbott Invests Additional $20M in Isis' Subsidiary Ibis Biosciences
Biopharmaceuticals
 HSMN NewsFeed - 24 Jun 2008
Genzyme and Isis Complete Licensing of Mipomersen
Biopharmaceuticals Licensing
 HSMN NewsFeed - 27 May 2008
Alnylam and Takeda Form Strategic Worldwide Platform Alliance in RNAi Therapeutics
Biopharmaceuticals
 HSMN NewsFeed - 25 Apr 2008
FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Apr 2008
Asuragen Launches Mirna Therapeutics
Diagnostics Biopharmaceuticals
 HSMN NewsFeed - 30 Mar 2008
Tekmira Pharmaceuticals and Protiva Biotherapeutics Announce Business Combination to Create Global Leader in RNAi Delivery and Therapeutics
Biopharmaceuticals
 HSMN NewsFeed - 11 Feb 2008
Regulus Therapeutics Appoints Peter S. Linsley, Ph.D. as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Jan 2008
Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity
Biopharmaceuticals Diagnostics Acquisitions
 HSMN NewsFeed - 7 Jan 2008
Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 14 Dec 2007
Isis Announces Appointment of B. Lynne Parshall as Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Dec 2007
Regulus Therapeutics Appoints Kleanthis G. Xanthopoulos, Ph.D. as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Oct 2007
Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes
Biopharmaceuticals Endocrinology
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.